Patidegib

Phase 2Small molecule

PPellePharm, Inc.

Patidegib is one of 37 small molecule programs targeting Basal Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Basal Cell CarcinomaActive, not recruiting

Basal Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

70 competitors in Basal Cell Carcinoma

#DrugCompanyPhaseTrials

Levulan

BBiomed Industries, Inc.

Opdivo

3 3

Voltaren

Novartis

Phase 2

1 4

Rocaltrol

Alnylam Pharmaceuticals

Phase 2

1 5

Opdualag

Bristol-Myers Squibb

Phase 2

1 6

Fabhalta

Regeneron

Phase 2

1 7

Yervoy

Bristol-Myers Squibb

Phase 2

1 8

Verteporfin PDT

Novartis

Phase 3

1 9

Sporanox

SSebela Pharmaceuticals Development LLC

Phase 2

2 10

Celebrex

PPhiladelphia Eye Associates

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Basal Cell Carcinoma

NCT06050122

Clinical

Trials by Indication[1]

Basal Cell Carcinoma3 trials

Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients

Completed·PPellePharm, Inc.·Phase 2·NCT02762084·17 enrolled

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

Active, not recruiting·SSol-Gel Technologies, Ltd.·Phase 3·NCT06050122·140 enrolled

Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas

Completed·PPellePharm, Inc.·Phase 2·NCT02828111·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Patidegib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Patidegib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Patidegib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PellePharm, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPellePharm, Inc.

Patidegib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Basal Cell Carcinoma3 trials

References

Drug Info

Quick Facts

Related News